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Increased Serum Activity of Matrix Metalloproteinase-9 in Patients with 
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Hyun Kim
Department of Internal Medicine, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea
Background/Aims: Matrix metalloproteinases (MMP)-2 and 
-9 can degrade essential components of vascular integrity. 
The aim of this study was to investigate the association be-
tween those MMPs and variceal bleeding (VB). Methods: 
Fifteen controls, 12 patients with acute ulcer bleeding (UB) 
group, 37 patients with varix (V group), and 35 patients with 
acute VB group were enrolled. Serum was obtained to mea-
sure MMP-2 and -9 activity by zymogram protease assays. 
Results: The activity levels of these compounds were com-
pared with the controls’ median value. The median MMP-
9 activity was 1.0 in controls, 1.05 in the UB group, 0.43 in 
the V group, and 0.96 in the VB group. The level of MMP-
9 activity was higher in the VB group than in the V group 
(p<0.001). In the VB group, there was a signiﬁ  cant decrease 
in MMP-9 activity over time after bleeding (p<0.001). The 
median MMP-2 activity level was 1.0 in controls, 1.01 in the 
UB group, 1.50 in the V group, and 1.55 in the VB group. The 
level of MMP-2 activity was similar in the VB and V groups. 
Conclusions: The level of MMP-9 activity increased in asso-
ciation with VB. The role of MMP-9 in the pathogenesis of VB 
should be veriﬁ  ed. (Gut Liver 2012;6:249-255)
Key Words: Hemorrhage; Esophageal and gastric varices; 
Matrix metalloproteinase 2; Matrix metalloproteinase 9
INTRODUCTION
Matrix metalloproteinase (MMP)-2 and -9 are members of 
the MMP family that can degrade several components of the 
extracellular matrix (ECM). MMP-2 is a gelatinase A or 72kDa 
type IV collagenase. MMP-9 is a gelatinase B or 92kDa type IV 
collagenase.
1 The substrates of MMP-2 and -9 are denatured 
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interstitial collagens (gelatins), type V collagen, and type IV col-
lagen.
1 These MMPs can cleave noncollagenous ECM including 
elastin, fibronectin, and laminin.
1
The collagen, elastin, fibronectin, and laminin support the 
cellular components of blood vessels.
2 These ECMs are impor-
tant for the maintenance of the structure of blood vessels. Ab-
normalities of the ECMs are associated with variety of vascular 
diseases.
3
The degrading effect of the ECM associated with MMP-2 and 
-9 plays an important physiological role in vascular remodel-
ing.
4-6 However, the over expression of MMP-2 and -9 is associ-
ated with pathologic changes in the vascular wall. The develop-
ment of aortic artery aneurysms is associated with an increased 
production or activity of MMP-2 and -9.
7-9 In cases with aneu-
rysm rupture, the MMP-2 and -9 are increased not only in the 
aortic wall but also in the blood.
7,10-13 The mechanisms involved 
in the development of aneurysm formation and rupture and the 
association of MMPs with this process may be attributed to the 
degradation of the ECM proteins and subsequent weakening of 
the aortic wall.
14 The blood and venous tissue levels of MMP-
2 and -9 are increased in varicose veins.
15-17 The expression 
and activity of these MMPs are increased in thrombophlebitic 
varicose veins.
16 The MMP-2 and -9 may be associated with the 
mechanism of the development of varicose veins and thrombo-
phlebitis formation. 
Gastroesophageal variceal bleeding (VB) is the most serious 
life threatening complication of cirrhosis. Important predictors 
of VB include large varices, decompensated cirrhosis (Child B or 
C), and the endoscopic findings of red whale marks.
18 Although 
the risk factors for VB have been evaluated by numerous prior 
studies, there are few reports explaining the mechanisms in-
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It is well known that the formation of gastroesophageal vari-
ces is attributed to increased portal pressure. In addition, there 
may be variceal ECM changes that enlarge and weaken the ves-
sel wall similar to the mechanism of the development of aortic 
aneurysms and varicose veins. We assume that there may be a 
marked increase of portal pressure before VB occurs. In addi-
tion, MMP-2 and -9 may also increase. Therefore, we hypoth-
esized that increased those MMPs may degrade vascular matrix 
proteins and induce VB. The aim of this study was to evaluate 
whether the changes of MMP-2 and -9 is associated with acute 
VB.
MATERIALS AND METHODS
1. Patients
Thirty five cirrhotic patients with acute VB group, 12 patients 
with acute gastric or duodenal ulcer bleeding (UB group), 37 
cirrhotic patients with varices (V group), and 15 healthy con-
trols were enrolled from January 2004 to December 2005. All 
patients and controls were Korean and admitted to Gil Hospital, 
Incheon, Korea. 
Patients with hematemesis or melena that showed fresh blood 
in the stomach and had bleeding stigmata on the varices or ac-
tive VB at endoscopy were considered to have acute VB. All 
bleeding signs and symptoms such as hematemesis and melena 
occurred within 6 hours prior to admission. One patient with 
gastric VB and 34 patients with esophageal VB were enrolled in 
this study. 
All cirrhotic patients in the V group had varix, but no current 
VB. They were admitted to the hospital for spontaneous bacteri-
al peritonitis (n=5), hepatic encephalopathy (n=3), jaundice (n=3), 
ascites (n=2), abdominal pain due to hepatocellular carcinoma 
(HCC) (n=1), and 23 patients had no specific symptoms. 
The types of esophageal varices were classified into three cat-
egories according to the report of Beppu et al.
19
Acute UB was defined in patients with hematemesis and 
melena that showed fresh blood in the stomach and bleeding 
stigmata on the ulcer or active UB at endoscopy. All bleeding 
signs and symptoms such as hematemesis and melena occurred 
within 6 hours prior to admission. Eleven patients with gastric 
UB and one patient with duodenal UB were enrolled. None of 
the enrolled patients had chronic viral hepatitis or liver cirrho-
sis. 
Fifteen controls were healthy and had no current or past his-
tory of liver diseases or any specific diseases. Their median age 
was 37 (29 to 62) years old and number of male was 9. 
2. Blood samples
The serum from patients with acute variceal or UB was col-
lected initially during routine blood examination when the pa-
tients were admitted to the emergency room. Subsequent serum 
sampling was obtained at 2 and 6 days after admission. How-
ever, the most patients with UB were usually discharged early, 
serum samples at 6 days were not obtained in those patients. 
The serum from the V group and controls was taken during 
visits to the hospital for the study period. However, the serum 
from the patients who have spontaneous bacterial peritonitis or 
hepatic encephalopathy, was obtained after all problems were 
resolved. All blood samples were stored at -70
oC for determina-
tion of MMPs and tumor necrosis factor (TNF)-α. 
3. Determination of the serum activity of MMP-2 and -9
The serum activity of MMP-2 and -9 were measured by zy-
mogram protease assays. Ten percent sodium dodecyl sulfate 
(SDS) polyacrylamide gels (acrylamide/bis acrylamide, 29/1) 
containing 0.05% gelatin were used for electrophoresis. Serum 
samples (containing 30 μg protein) were prepared with standard 
SDS-gel-loading buffer (0.1% SDS). Electrophoresis was per-
formed at 60 V for 6 hours and then the gel was washed twice 
with 100 mL distilled water containing 2.5% Triton X-100 on 
a shaker for 30 minutes at room temperature. The gel was then 
incubated in 100 mL developing buffer (50 mM Tris-HCl, 0.2 
M NaCl, 5 mM CaCl2, 1% Triton X-100) for 16 hours at 37
oC, 
stained with Coomassie brilliant blue R-250, and destained with 
methanol-acetic acid-water (50:75:875, v:v:v).
4. Quantiﬁ  cation of MMPs activity
Relative MMP activity was quantified by scanning the zymo-
gram photograph on a gel documentation and analysis system 
(Kodak Image Station 4000MM; Eastman Kodak, Rochester, 
NY, USA). To normalize the possible difference between zymo-
graphs, two healthy control samples were used for each gel to 
serve as internal controls. The digitized data of each photograph 
were normalized by their own internal controls.
5. Determination of serum TNF-α level
The serum level of TNF-α was determined by an enzyme-
linked immunosorbent assay (ELISA, Endogen Human TNF-α 
ELISA kit; Pierce Biotechnology Inc., Rockford, IL, USA).
6. Statistical analysis
Continuous variables were expressed as the median and 
range. The Mann-Whitney non-parametric test was used for 
comparing continuous variables between groups. Within group, 
the Wilcoxon signed-rank test or Friedman test were used for 
the comparison of each change of MMP-2, -9, and TNF-α. The 
χ
2-test or Fisher’s exact test were used for comparing categori-
cal variables between groups. A p-value less than 0.05 was 
considered statistically significant. The SPSS version 12.0 (SPSS 
Inc., Chicago, IL, USA) was used for statistical analysis. Kwon OS, et al: MMP-9 & Variceal Bleeding  251
RESULTS
1. Comparison of clinical characteristics and hemodynamic 
values between the VB and UB groups 
The median age and sex ratio were not different between the 
VB and UB groups. The levels of AST, ALT, and total bilirubin 
were higher and prothrombin time was more prolonged in the 
VB group than in the UB group. The level of albumin, hemoglo-
bin, and platelet count were lower in the VB group compared to 
the UB group (Table 1). 
Hemodynamic values such as systolic, diastolic, mean arterial 
blood pressure, and pulse rate were not different between the 
two groups. The amount of blood transfusion and intravenous 
fluid administration during the initial 24 hours were not differ-
ent between the two groups (Table 2).
2. Comparison of clinical characteristics and hemodynamic 
values between the VB and varix groups 
The median age was higher in the VB than in V groups. The 
sex ratio and causes of cirrhosis were not different between the 
two groups. Alcohol was the most common cause of cirrhosis 
in both two groups. The levels of AST, ALT, total bilirubin, 
platelet count, albumin, prothrombin time, and the distribution 
of Child-Pugh class were not different between the two groups. 
The hemoglobin level was lower in the VB group than in the 
V group. The size of the varix was not different between the 
two groups. The frequency of HCC was not different between 
the two groups. Except for one case of HCC, all HCC cases had 
Table 1. Baseline Clinical and Laboratory Characteristics
Characteristic Ulcer bleeding (n=12) p-value Varix bleeding (n=35) p-value Varix (n=37)
Age, yr
Sex, male/female
Causes
  Alcohol
  HBV
  HCV
  Cryptogenic
AST, U/L
ALT, U/L
Total bilirubin, mg/dL
Albumin, g/dL
Hemoglobin, g/dL
Platelet, ×10
3/μL
PT, sec
Varix size, F1/F2/F3
Child-Pugh class, A/B/C
HCC
51 (37-88)
10/2
17 (11-28)
12 (5-234)
0.6 (0.4-0.9)
3.5 (3.1-4.6)
10.0 (2.8-12.9)
 262 (205-425)
 12.6 (12.1-14.3)
0.641
0.703
<0.001
0.005
<0.001
<0.001
0.033
<0.001
<0.001
50 (30-85)
26/9
23
  7
  4
  1
64 (7-1143)
26 (7-690)
 2.2 (0.7-13.5)
2.9 (1.9-4.1)
 8.3 (3.0-14.8)
103 (35-241)
16.9 (12.7-60)
6/18/11
6/17/12
4
0.027
0.4
0.089
0.195
0.963
0.297
0.125
<0.001
0.112
0.083
0.468
0.97
0.736
58 (34-72)
31/6
18
17
  1
  1
 47 (19-256)
26 (7-156)
 2.9 (0.3-18.6)
3.1 (1.8-4.5)
11.0 (7.9-17.5)
75 (23-242)
15.2 (11.5-26.2)
8/22/7
7/17/13
6
Data are presented as numbers of patients or the median (range).
HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; HCC, hepa-
tocellular carcinoma. 
Table 2. Baseline Hemodynamic Values and Patient Management
Ulcer bleeding (n=12) p-value Varix bleeding (n=35) p-value Varix (n=37)
BP, mm Hg
  Systolic BP
  Diastolic BP
  Mean arterial BP
Pulse rate, /min
Managements
  IV fluid, mL
  Blood transfusion, P
100 (70-140)
 60 (40-100)
77 (50-113)
84 (78-106)
 3,000 (2,180-5,100)
3 (1-6)
0.844
0.8
0.624
0.292
0.617
0.444
100 (50-150)
60 (0-90)
77 (25-110)
87 (68-156)
 3,076 (1,730-4,880)
3 (1-7)
 0.024
 0.003
 0.018
<0.001
113 (90-148)
70 (50-90)
83 (63-108)
72 (52-92)
Data are presented as number of patients or the median (range).
BP, blood pressure; IV, intravenous; P, pack.252  Gut and Liver, Vol. 6, No. 2, April 2012
a stage less than III (according to the modified International 
Union against Cancer Tumor-Node-Metastasis stage) (Table 1). 
The systolic, diastolic, and mean arterial pressures were lower 
in the VB group than in the V group. The heart rate was more 
rapid in the VB group than in the V group (Table 2). Beta block-
er had been administrated to 11 patients in the VB group and 
21 patients in the V group prior to enrollment. 
3. Serum activity of MMP-9 in controls and patients at en-
rollment
The median serum activity of MMP-9 in the V group (0.43; 
range, 0.14 to 1.31) was the lowest value among all patient 
groups and controls. The MMP-9 activity in the UB group at 
bleeding (1.05; range, 0.83 to 1.31) was not different from 
controls (1.0; range, 0.7 to 1.4). The MMP-9 activity in the VB 
group at bleeding (0.96; range, 0.5 to 4.24) was higher than in 
the V group (p<0.001) (Figs 1 and 2A).
4. Change of serum activity of MMP-9 after bleeding 
The median serum activity of MMP-9 activity in the UB 
group was significantly decreased from 1.05 to 0.89 (0.77 to 1.22) 
at bleeding and 2 days after bleeding, respectively (p=0.015) (Fig. 
1). 
The MMP-9 activity in the VB group decreased over time 
(p<0.001). The MMP-9 activity decreased from 0.96 at bleeding 
to 0.81 (0.32 to 2.39) after 2 days (p<0.001), and to 0.65 (0.15 to 
1.33) after 6 days after bleeding (p=0.01) (Figs 1 and 2B).
5. Serum activity of MMP-2 in patients and controls at en-
rollment
The median serum activity of MMP-2 in controls (1.0; range, 
0.85 to 1.16) was not different from the UB group (1.01; range, 
0.59 to 2.2) at bleeding. The MMP-2 activity in the VB group 
(1.55; range, 0.38 to 7.01) at bleeding was not different from the 
V group (1.5; range, 0.97 to 1.85). Its activity in the UB group at 
bleeding was lower than in the VB group at bleeding (p=0.002) 
and the V group (p=0.001) (Figs 2A and 3). 
6. Change of serum activity of MMP-2 after bleeding
The median serum activity of MMP-2 in the UB group was 
decreased from 1.01 at bleeding to 0.95 (0.45 to 2.68) at 2 days 
after bleeding. However, there was no significant change in its 
activity between the two time points. The MMP-2 activity in the 
VB group decreased from 1.55 at bleeding to 1.49 (0.37 to 4.42) 
at 2 days (p>0.05), and to 1.44 (0.27 to 6.42) at 6 days (p>0.05) 
after bleeding. There was no significant change in its activity 
between each two time points (Fig. 3).
7. Basal serum TNF-α level and change of serum TNF-α 
level after bleeding
The median serum level of TNF-α was less than 1 pg/mL in 
controls and the UB group at bleeding. The TNF-α level in the 
VB group (52.5; range, 7.8 to 182.7 pg/mL) at bleeding was 
higher than that in the V group (23.7; range, 0 to 195.4 pg/
mL). The TNF-α level was very high in the V group and the 
VB group at bleeding compared to controls and the UB group 
(p<0.001) (Fig. 4).
The TNF-α level in the UB group was remained at a very low 
level at 2 days after bleeding. The TNF-α level in the VB group 
was decreased from 52.5 pg/mL at bleeding to 44.8 pg/mL (range, 
12.8 to 302 pg/mL) at 2 days (p>0.05), and decreased to 39 pg/
mL (range, 8.9 to 157.6 pg/mL) at 6 days (p>0.05) after bleeding. 
There was no significant change in the level of TNF-α between 
each two time points (Fig. 4).
DISCUSSION 
The serum activity of MMP-9 might increase before VB and 
Fig. 1. Relative median serum activity of matrix metalloproteinase 
(MMP)-9. After the median serum activity of MMP-9 in controls is 
determined to be 1.0, each measurement of MMP-9 serum activity is 
compared with the controls’ median value. 
Day 0, at the time of bleeding; Days 2 and 6, days after bleeding.
Fig. 2. The serum activity levels of matrix metalloproteinase (MMP)-
2 and -9 are measured using zymogram protease assays. (A) The level 
of MMP-9 activity is lowest in the varix group. The level of MMP-2 
activity is higher in the varix group and varix bleeding group at the 
time of bleeding compared with the controls and ulcer bleeding group 
at the time of bleeding. (B) The level of MMP-9 activity decrease over 
time. 
Day 0, at the time of bleeding; Days 2 and 6, days after bleeding. Kwon OS, et al: MMP-9 & Variceal Bleeding  253
subsequently decrease to basal level over time. The MMP-
9 activity in the VB group at bleeding was higher than in the 
V group that had varix without current bleeding. The MMP-9 
activity in the VB group subsequently decreased to basal level 
that was still higher level than that in the V group. Therefore, 
the serum activity of MMP-9 might have increased before VB. 
Although it was not possible to measure the serum activity of 
MMP-9 just before and at the time of on set of bleeding, the 
following evidences might support the above possibility. First, 
all patients with VB in this study had bleeding related signs and 
symptoms within 6 hours before admission. Second, blood sam-
ples were collected immediately in the emergency department 
when the patients were admitted. Third, seventeen patients (50%) 
in the VB group had current active bleeding at endoscopy. 
Fourth, the sudden hemodynamic change due to acute blood 
loss occurred in both the VB group and UB group. However, the 
increased MMP-9 activity was observed only in the VB group. 
Fifth, one VB case had re-bleeding at 8 days after bleeding. The 
MMP-9 activity in this case decreased from 1.34 at bleeding 
to 0.76 after 2 days, but re-increased to 0.89 after 6 days after 
bleeding. Therefore, the MMP-9 activity might be increased be-
fore VB and the increased MMP-9 activity may be involved in 
the mechanisms associated with VB.
In this study, the basal MMP-9 activity in the V group was 
the lowest among all patient groups and controls. The MMP-9 
activity is low in cirrhotic patients compared to normal controls 
and decreases over time as chronic liver disease progresses to 
liver cirrhosis.
20-22 The reason why the MMP-9 activity is low 
in cirrhotic patients compared to healthy controls is unclear. 
Further study is needed to evaluate the role of MMP-9 in the 
pathogenesis of liver cirrhosis.
MMP-9 plays an important role in aortic aneurysm forma-
tion
7-9 and rupture,
7,10-13 this has been demonstrated in experi-
mental models of aortic aneurysm formation in mice.
23 MMP-
9 is the most abundantly expressed MMP in aortic aneurysm 
tissue, it is produced mainly by the aneurysm-infiltrating 
macrophages.
7 It is also detected in the liver and is produced 
mainly by Kupffer cells.
1 It is increased in the histological layers 
of varicose veins and associated with thrombophlebitic varicose 
veins.
16 Therefore, increased MMP-9 is associated with inflam-
mation and tissue macrophages. Some have suggested that in-
fection and inflammation are associated with the development 
of VB. Bacterial infections have been documented in 35% to 
66% of cirrhotic patients with VB.
24 The endotoxemia secondary 
to bacterial infection may be occurred and increase portal pres-
sure by induction of endothelin, the most potent vasoconstrictor 
in portal vein.
25 These effects induce sudden increases of portal 
vein pressure in patients that already have large varices with 
high wall tension and portal pressure, and finally lead to VB.
25 
In addition, we hypothesize that the sudden increased serum 
activity of MMP-9 might degrade the ECM that supports the 
vessel wall and finally lead to VB. Although we did not evalu-
ate directly whether the endotoxemia could induce MMP-9, it is 
possible that the increased MMP-9 activity might be associated 
with the endotoxemia through induction of TNF-α in cirrhotic 
patients.
26-30 
TNF-α is a potent inflammatory cytokine that has a variety 
of functions and is induced by endotoxin.
26 TNF-α promotes 
MMP-9 induction through the activation of the NF-κB path-
way.
27-30 Therefore we investigated whether change of the serum 
TNF-α level in VB paralleled the change of MMP-9 activity over 
time. The increasing and decreasing patterns of TNF-α level 
was similar to those of the MMP-9 activity in the VB group 
although the TNF-α level was not significantly decreased after 
bleeding event. Therefore, TNF-α appears to play an important 
Fig. 3. Relative median serum activity level of matrix metalloprotein-
ase (MMP)-2. The median serum activity of MMP-2 in the controls is 
considered to be 1.0; the serum activity of MMP-2 is expressed by a 
comparison with the median value observed among the controls. 
Day 0, at the time of bleeding; Days 2 and 6, days after bleeding.
Fig. 4. The median level of serum tumor necrosis factor (TNF)-α. 
Day 0, at the time of bleeding; Day 2 and 6, days after bleeding.254  Gut and Liver, Vol. 6, No. 2, April 2012
role in the mechanism associated with VB and may initiate an 
increase in MMP-9 activity. However, further study is needed to 
evaluate the factors involved in initiating increase of TNF-α and 
determines whether the endotoxin increases TNF-α and MMP-
9 activity sequentially. And additional study is also needed to 
investigate whether the increase in MMP-9 activity is the simple 
reflection of the increase of TNF-α or really associated with de-
struction of vascular wall. 
An important risk factor associated with VB is red marks or 
red spots on the varix. Histological studies of esophageal trans-
action rings from the area of bleeding show that the red spots 
on varices are dilated blood-filled channels that are not lined by 
endothelial cells and basement membrane.
31 The endothelial cell 
is an important cell that secretes many vasoactive substances 
and regulates vascular tone.
32 The basement membrane is es-
sential for the survival and function of the endothelial cell.
33 
Portions without endothelial cells and basement membrane in 
blood vessels may be vulnerable to changes in vascular pres-
sure, and subsequently may be easily ruptured. Type IV col-
lagen is the major ECM component of basement membrane.
34 
MMP-9 has a strong proteolytic effect on type IV collagen.
1 Its 
increase might induce weakening of the basement membrane 
and detachment of endothelial cells. Therefore, increased MMP-
9 activity may be associated with the mechanism of VB. 
After bleeding, the MMP-9 activity in the UB group decreased 
slightly over time. The cause of the decrease in the MMP-9 ac-
tivity is unclear. However, the hemodynamic supports with in-
travenous fluid administration might have had a dilution effect 
on the MMP-9 activity. Compared to the UB group, the MMP-
9 activity in the VB group remarkably decreased over time. This 
decreasing pattern means that the MMP-9 activity returns to the 
basal level over time after bleeding. 
The MMP-9 is associated with tumor invasiveness and me-
tastasis in HCC by its proteolytic effect of surrounding ECM.
35 
In this study, all of HCC cases were not advanced stage. The 
prevalence of HCC was not different between V and VB groups. 
Even if cases with HCC were excluded in analysis, the MMP-9 
activity in VB group at bleeding was still increased than that in 
V group (data not shown). 
In contrast to the MMP-9, the serum activity of MMP-2 in 
the VB group at bleeding was not different from the V group. In 
addition, there was no significant change of the MMP-2 activity 
after bleeding. Therefore, MMP-2 dose not appear to be associ-
ated with VB. 
The MMP-2 activity in liver tissues and blood increases when 
chronic liver disease progresses to liver cirrhosis
20,21,36 because 
hepatic stellate cells that mainly produce the MMP-2 in the liver 
are activated.
1 In this study, the MMP-2 activity in all cirrhotic 
patients was higher than that in controls and the UB group. 
The limitations of this study included the followings. First, 
this study indirectly evaluated the role of MMP-9 in the mecha-
nism of VB. Further study that can elucidate the mechanism 
through in vitro or in vivo experiments is needed. Second, se-
rum samplings were not taken before VB. Serial samplings be-
fore VB are needed to elucidate whether the MMP-9 activity is 
increased before onset of VB. Third, there is possibility that the 
increased MMP-9 activity is simple reflection of the associated 
conditions with VB such as endotoxemia or acutely decreased 
liver function. Comparison study between endotoxemia with 
and without VB, and between UB and VB in patients with liver 
cirrhosis is needed.
In conclusion, the increased serum activity of MMP-9 present 
at VB in cirrhotic patients may be associated with the mecha-
nism of VB. The increased MMP-9 activity may be involved in 
the destruction of the variceal matrix and facilitate rupture of 
the varix. Further studies are needed to specifically determine 
the pathophysiology of this process. 
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